HubXchange brings together executives from pharma and biotech to address and find solutions to the key issues faced in AI-led drug discovery. In this talk, Bryn Williams-Jones, VP Drug Discovery, will explore how he bridges the world’s of science and technology to help guide technologists in their work to develop AI tools that meet hyper-specific scientific requirements. He will then demonstrate how BenevolentAI applies these tools to empower target identification and precision medicine. Bryn will cite case studies from BenevolentAI’s work in novel target discovery, drug repurposing and in collaboration with AstraZeneca.
Bryn is responsible for driving the application of AI-augmented drug discovery to disease hypothesis generation across the BenevolentAI portfolio bringing together the key scientific and AI strands of research. Before joining BenevolentAI Bryn lead the Open PHACTS IMI project, and is CEO of the Open PHACTS Foundation project building open semantic web infrastructure for drug discovery. Prior to that Bryn worked at Pfizer across a wide range of Therapeutic Areas applying data and computational science to early drug discovery hypothesis generation.
